BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT05028608
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 76
- Registration Number
- NCT05026320
- Locations
- 🇩🇪
Deutsche Sporthochschule Köln (DSHS), Köln, Nordrhein-Westfalen, Germany
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45000
- Registration Number
- NCT05022758
- Locations
- 🇰🇷
Many locations, Multiple Locations, Korea, Republic of
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 951
- Registration Number
- NCT05013008
- Locations
- 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇺🇸Florida Kidney Physicians - Fort Lauderdale, Fort Lauderdale, Florida, United States
🇺🇸Indago Research & Health Center, Inc., Hialeah, Florida, United States
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 336376
- Registration Number
- NCT05004428
- Locations
- 🇨🇦
Many Locations, Multiple Locations, Canada
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT05003089
- Locations
- 🇳🇱
Center for Human Drug Research, Leiden, Netherlands
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 47
- Registration Number
- NCT04999202
- Locations
- 🇺🇸
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States
🇺🇸Florida Cancer Specialists, Altamonte Springs, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 843
- Registration Number
- NCT04993989
- Locations
- 🇩🇪
Many Locations, Multiple Locations, Germany
A Study to Learn More About How a Smartphone App Called MyIUS Predicts Future Menstrual Bleeding in Women After They Have Begun Using Intrauterine Birth Control Method (a Birth Control Device is Inserted Into a Woman's Uterus by Her Doctor)
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3045
- Registration Number
- NCT04989595
- Locations
- 🇸🇪
Many Locations, Multiple Locations, Sweden
A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT04981431
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan
© Copyright 2024. All Rights Reserved by MedPath